-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the intensification of aging and the continuous upgrading of consumption, the general health industry continues to show a strong development trend
.
According to incomplete statistics, the scale of the health industry market has reached 7 trillion in 2020, and it is estimated that it will reach 8 trillion in 2021
.
In the context of the vigorous development of the big health industry, the concept of big health continues to be hot.
Some traditional pharmaceutical companies have begun to use the "health" brand to try to break the single product structure across the border.
Among them, tea is the cross-border choice of many pharmaceutical companies.
One of
.
Recently, the "Zhenyinzi" tea brand under Huabei Pharmaceutical, a traditional pharmaceutical company, has announced that it is about to start attracting investment
.
The tea brand has a "national tide" health feature in its publicity.
According to the description of North China Pharmaceutical on August 19, 2021, the first day of trial operation set a record of nearly 8,000 yuan in single store revenue, which will win the opening of new stores in the future.
Caitou
.
According to related reports, the first store has closed the takeaway service due to the high number of customers queuing up
.
In addition, tea brands will start to attract investment, and investment information is already being produced
.
It is understood that the "Zhenyinzi" brand belongs to Hebei Huawei Health Industry Co.
, Ltd.
, and North China Pharmaceutical holds 51% of the company's equity
.
From the perspective of business scope, North China Pharmaceuticals is mainly engaged in the R&D, production and sales of pharmaceutical products.
The products involve chemical drugs, biological drugs, health consumer products, etc.
The therapeutic areas include anti-infective drugs, cardiovascular and cerebrovascular drugs, kidney disease and immune regulation drugs, cancer therapy drugs, vitamins and health consumer goods
.
The analysis believes that North China Pharmaceutical's new tea business is mainly to seek new growth points
.
Judging from the financial reports of North China Pharmaceuticals in the past two years, the overall performance of the performance has been relatively sluggish.
In 2020, the company’s net profit attributable to its parent will drop by 43.
46% year-on-year; the third quarter report of 2021 shows that in the first three quarters of this year, the net profit of North China Pharmaceutical attributable to its parent will decline year-on-year.
87.
58%
.
For the tea business, North China Pharmaceutical is not the only one in the market.
For example, Golden Throat launched the Golden Throat herbal beverage in 2016; the beverage product Wanglaoji launched by Guangzhou Pharmaceutical Group has become popular in the beverage market; Jiangzhong Group is building Hericium erinaceus The monkey mushroom beverage was launched based on biscuit products; Tong Han Chuntang, a pharmacy with a history of more than two hundred years, also opened a Guochao milk tea shop; through cross-border cooperation, Tongrentang launched the "Knowing Health" brand, which combines "Chinese herbal medicine + coffee".
"Combined together, to attract young people to check in, the pharmacy also launched Tongrentang herbal tea and Tongrentang maca oolong, continuing to make a fortune in the tea business
.
In the face of fierce competition in the market, traditional pharmaceutical companies have become more frequent and diverse
.
In addition to tea, business areas such as daily chemicals, beauty and even lotteries have also become cross-border choices of pharmaceutical companies in recent years
.
It is worth mentioning that it is easy for traditional pharmaceutical companies to cross-border early adopters by hunting for novelties, but it is also difficult for them to succeed in cross-border non-medical fields
.
In terms of tea business, in the current tea market, with the exception of Wang Laoji, a subsidiary of Guangyao, the teas launched by other pharmaceutical companies seem to be dreamlike, and the reputation is not lasting.
The golden voice of the layout of herbal beverages is even more because of tea.
Drinking losses has dragged down its own profitability
.
According to the company's 2016 financial report, the company achieved a revenue of 768 million yuan for the year, an increase of 8.
7% year-on-year, and a net profit of 103 million yuan, a year-on-year decrease of 33.
4%
.
In this regard, it is also reminded that traditional pharmaceutical companies that want to play a new national trend through cross-border fun, it is not easy for pharmaceutical companies to enter other fields, and they need to pass multiple tests in terms of brand power and channels, plus tea and other fields.
There are many pioneers, and it may not be easy for pharmaceutical companies to open a new situation by relying on cross-border business alone
.
.
According to incomplete statistics, the scale of the health industry market has reached 7 trillion in 2020, and it is estimated that it will reach 8 trillion in 2021
.
In the context of the vigorous development of the big health industry, the concept of big health continues to be hot.
Some traditional pharmaceutical companies have begun to use the "health" brand to try to break the single product structure across the border.
Among them, tea is the cross-border choice of many pharmaceutical companies.
One of
.
Recently, the "Zhenyinzi" tea brand under Huabei Pharmaceutical, a traditional pharmaceutical company, has announced that it is about to start attracting investment
.
The tea brand has a "national tide" health feature in its publicity.
According to the description of North China Pharmaceutical on August 19, 2021, the first day of trial operation set a record of nearly 8,000 yuan in single store revenue, which will win the opening of new stores in the future.
Caitou
.
According to related reports, the first store has closed the takeaway service due to the high number of customers queuing up
.
In addition, tea brands will start to attract investment, and investment information is already being produced
.
It is understood that the "Zhenyinzi" brand belongs to Hebei Huawei Health Industry Co.
, Ltd.
, and North China Pharmaceutical holds 51% of the company's equity
.
From the perspective of business scope, North China Pharmaceuticals is mainly engaged in the R&D, production and sales of pharmaceutical products.
The products involve chemical drugs, biological drugs, health consumer products, etc.
The therapeutic areas include anti-infective drugs, cardiovascular and cerebrovascular drugs, kidney disease and immune regulation drugs, cancer therapy drugs, vitamins and health consumer goods
.
The analysis believes that North China Pharmaceutical's new tea business is mainly to seek new growth points
.
Judging from the financial reports of North China Pharmaceuticals in the past two years, the overall performance of the performance has been relatively sluggish.
In 2020, the company’s net profit attributable to its parent will drop by 43.
46% year-on-year; the third quarter report of 2021 shows that in the first three quarters of this year, the net profit of North China Pharmaceutical attributable to its parent will decline year-on-year.
87.
58%
.
For the tea business, North China Pharmaceutical is not the only one in the market.
For example, Golden Throat launched the Golden Throat herbal beverage in 2016; the beverage product Wanglaoji launched by Guangzhou Pharmaceutical Group has become popular in the beverage market; Jiangzhong Group is building Hericium erinaceus The monkey mushroom beverage was launched based on biscuit products; Tong Han Chuntang, a pharmacy with a history of more than two hundred years, also opened a Guochao milk tea shop; through cross-border cooperation, Tongrentang launched the "Knowing Health" brand, which combines "Chinese herbal medicine + coffee".
"Combined together, to attract young people to check in, the pharmacy also launched Tongrentang herbal tea and Tongrentang maca oolong, continuing to make a fortune in the tea business
.
In the face of fierce competition in the market, traditional pharmaceutical companies have become more frequent and diverse
.
In addition to tea, business areas such as daily chemicals, beauty and even lotteries have also become cross-border choices of pharmaceutical companies in recent years
.
It is worth mentioning that it is easy for traditional pharmaceutical companies to cross-border early adopters by hunting for novelties, but it is also difficult for them to succeed in cross-border non-medical fields
.
In terms of tea business, in the current tea market, with the exception of Wang Laoji, a subsidiary of Guangyao, the teas launched by other pharmaceutical companies seem to be dreamlike, and the reputation is not lasting.
The golden voice of the layout of herbal beverages is even more because of tea.
Drinking losses has dragged down its own profitability
.
According to the company's 2016 financial report, the company achieved a revenue of 768 million yuan for the year, an increase of 8.
7% year-on-year, and a net profit of 103 million yuan, a year-on-year decrease of 33.
4%
.
In this regard, it is also reminded that traditional pharmaceutical companies that want to play a new national trend through cross-border fun, it is not easy for pharmaceutical companies to enter other fields, and they need to pass multiple tests in terms of brand power and channels, plus tea and other fields.
There are many pioneers, and it may not be easy for pharmaceutical companies to open a new situation by relying on cross-border business alone
.
